Patients will be included with a stable but active disease (as defined Diagnosis of systemic sclerosis according to ACR/EULAR classification by EUSTAR ≥2.5) or to patients with a worsening disease despite low dose steroids and at least 2 immunosuppressive treatment including DMARDs (methotrexate, azathioprine, mycophenolate mofetil) and/or a biological DMARD (rituximab or tocilizumab) for at least 6 months.

1 total trials

Filter these 1 trials by phase, country, sponsor and more.

Open in Search →

Showing 1–1 of 1 trials